Drugs / Montmorillonite Power
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05252546 | Mar → Aug 2022 | HER2 positive breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Montmorillonite Power | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05252546 ↗ |